<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10282130</article-id><article-id pub-id-type="pmcid-ver">PMC10282130.1</article-id><article-id pub-id-type="pmcaid">10282130</article-id><article-id pub-id-type="pmcaiid">10282130</article-id><article-id pub-id-type="pmid">37350960</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1160312</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tao</surname><given-names initials="H">Heqing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="Z">Zhou</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Dong</surname><given-names initials="Y">Yongqiang</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1359617"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="L">Ligang</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2112240"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Peng</surname><given-names initials="L">Liang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/966744"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="X">Xueqing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Department of Neurology, Peking University Third Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Deartment of Thyroid Surgery, First Affiliated Hospital of Zhengzhou University</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University</institution>, <addr-line>Columbus, OH</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Murugaiyan Gopal, Harvard Medical School, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Sunil Martin, Rajiv Gandhi Centre for Biotechnology, India; Ying Liang, Florida International University, United States; Shrishti Saxena, Brigham and Women&#8217;s Hospital and Harvard Medical School, United States</p></fn><corresp id="fn001">*Correspondence: Liang Peng, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:wsfirefly@126.com">wsfirefly@126.com</email>; Yongqiang Dong, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:edwin@bjmu.edu.cn">edwin@bjmu.edu.cn</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427662</issue-id><elocation-id>1160312</elocation-id><history><date date-type="received"><day>07</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>5</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>22</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-23 17:25:09.663"><day>23</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Tao, Yu, Dong, Liu, Peng and Chen</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Tao, Yu, Dong, Liu, Peng and Chen</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-14-1160312.pdf"/><abstract><sec><title>Background</title><p>To assess the causal role of lipid traits and lipid-lowering agents in inflammatory bowel disease (IBD).</p></sec><sec><title>Methods</title><p>Univariable mendelian randomization (MR) and multivariable MR (MVMR) analyses were conducted to evaluate the causal association between low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and IBD. Drug-targeted MR analyzed the effects of lipid-lowering drugs on IBD, and network MR was used to analyze potential mediation effects.</p></sec><sec><title>Results</title><p>The levels of HDL-C had an inverse relationship with the risk of Crohn&#8217;s disease (CD, OR: 0.85, 95% CI: 0.73-0.98, <italic toggle="yes">P</italic> = 0.024). In MVMR, the inverse relationships were found in all three outcomes. Drug-targeted MR analyses showed that with one-SD LDL-C decrease predicted by variants at or near proprotein convertase subtilisin/kexin type 9 (<italic toggle="yes">PCSK9)</italic>, the OR values of people diagnosed with IBD, ulcerative colitis (UC) and CD were 1.75 (95%CI: 1.13-2.69, <italic toggle="yes">P</italic> = 0.011), 2.1 (95%CI: 1.28-3.42, <italic toggle="yes">P</italic> = 0.003) and 2.24 (95%CI: 1.11-4.5, <italic toggle="yes">P</italic> = 0.024), respectively. With one-SD LDL-C decrease predicted by variants at or near cholesteryl ester transfer protein <italic toggle="yes">(CETP)</italic>, the OR value of people diagnosed with CD was 0.12 (95%CI: 0.03-0.51, <italic toggle="yes">P</italic> = 0.004). Network-MR showed that HDL-C mediated the causal pathway from variants at or near <italic toggle="yes">CETP</italic> to CD.</p></sec><sec><title>Conclusion</title><p>Our study suggested a causal association between HDL-C and IBD, UC and CD. Genetically proxied inhibition of <italic toggle="yes">PCSK9</italic> increased the risk of IBD, UC and CD, while inhibition of <italic toggle="yes">CETP</italic> decreased the risk of CD. Further studies are needed to clarify the long-term effect of lipid-lowering drugs on the gastrointestinal disorders.</p></sec></abstract><kwd-group><kwd>lipids</kwd><kwd>lipid-lowering</kwd><kwd>inflammatory bowel disease</kwd><kwd>Mendelian randomization</kwd><kwd><italic toggle="yes">PCSK9</italic></kwd><kwd><italic toggle="yes">CTEP 2</italic></kwd></kwd-group><funding-group><funding-statement>This study was supported in part by a grant from the Guangdong Natural Science Foundation(2018A030313970) and (2021A1515110491) managed by LP and HT, National Natural Science Foundation of the P.R. China (81900521) and Programs for Science and Technology Development of Henan province (SBJ202003033) managed by YD. The funders of the study had no role in the study design, data collection, analysis, interpretation, writing of the report, or decision to submit for publication.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="0"/><equation-count count="0"/><ref-count count="37"/><page-count count="8"/><word-count count="3317"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Inflammatory bowel disease (IBD) is chronic intestinal inflammation disease with an incidence of over 0.3%. It includes ulcerative colitis (UC) and Crohn&#8217;s disease (CD), causing a significant disease burden (<xref rid="B1" ref-type="bibr">1</xref>). Patients with IBD often have high levels of low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and low level of high-density lipoprotein cholesterol (HDL-C) (<xref rid="B2" ref-type="bibr">2</xref>, (<xref rid="B3" ref-type="bibr">3</xref>). Dyslipidemia may also contribute to the development of IBD. Koutroumpakis et&#160;al. found that persistent dyslipidemia was associated with disease activity in patients with IBD (<xref rid="B3" ref-type="bibr">3</xref>). Lower HDL-C was associated with an increased risk of poor outcomes, such as surgery and tumors in IBD patients (<xref rid="B4" ref-type="bibr">4</xref>). Additionally, evidence suggests that lower HDL-C in childhood may be associated with the subsequent diagnosis of IBD (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>In recent years, some researchers have recommended early evaluation and intervention of lipid levels to prevent new-onset IBD and improve the prognosis in patients with IBD. Statins, a widely used medication to lower LDL-C, have been found to have a protective effect against new-onset IBD, CD, and UC (<xref rid="B6" ref-type="bibr">6</xref>). Similarly, a population-based case-control study in Sweden showed that statins were associated with a lower risk of CD (<xref rid="B7" ref-type="bibr">7</xref>). In addition, the use of statins in UC patients was found to be associated with a reduction in steroid hormone dosage (<xref rid="B8" ref-type="bibr">8</xref>). Furthermore, transcriptomic analysis found that atorvastatin had the highest negative correlation with the UC gene signature, suggesting that statins may be potential therapies for IBD (<xref rid="B9" ref-type="bibr">9</xref>). However, the therapeutic effect of statins on IBD is controversial (<xref rid="B10" ref-type="bibr">10</xref>). Khalil et&#160;al. found that statins did not prevent new-onset IBD (<xref rid="B11" ref-type="bibr">11</xref>). Dhamija et&#160;al. reported that statin therapy was not associated with beneficial effects in patients with UC (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>The contradictory findings in these studies highlight the need for further investigation into the potential role of statins in IBD. However, observational studies are limited by inherent constraints, including residual confounding and reverse causality (<xref rid="B12" ref-type="bibr">12</xref>). Additionally, lipid-lowering drugs have extensive immunomodulatory effects (<xref rid="B13" ref-type="bibr">13</xref>). which raises the question of whether their effect on IBD is mediated through lipid lowering or immunomodulatory mechanisms. Therefore, it is essential to elucidate the underlying mechanisms of the potential therapeutic effect of statins in IBD.</p><p>Mendelian randomization (MR) is a powerful tool for assessing the causal effects of exposure factors on outcomes. It utilizes genetic variation randomly allocated at conception as instrumental variables (IVs), allowing for the evaluation of causality in a way that is less susceptible to confounding factors (<xref rid="B12" ref-type="bibr">12</xref>). Univariate MR requires that the instrumental variable satisfies three assumptions: first, it must be associated with the exposure; second, it must be independent of the outcome given the exposure; and third, it must be independent of all known confounders (<xref rid="B14" ref-type="bibr">14</xref>). Multivariate MR (MVMR) is an extension of MR that leverages genetic variation associated with multiple potentially relevant exposures to estimate the direct effect of each exposure on a single outcome (<xref rid="B14" ref-type="bibr">14</xref>). Drug-target MR analysis uses the genetic variants within or near the gene that encodes the targeted protein as IVs to predict efficacy (<xref rid="B15" ref-type="bibr">15</xref>). In this study, we applied the latest genome-wide association study (GWAS) from UK Biobank on lipids as IVs to study the relationship between lipids and IBD. Additionally, we employed drug-target MR analysis to investigate the effect of lipid-lowering drugs on IBD.</p></sec><sec sec-type="materials|methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2_1"><label>2.1</label><title>GWAS data source</title><p>The data used in this study on IBD patients were obtained from the FinnGen study conducted in 2021 (<xref rid="B16" ref-type="bibr">16</xref>). The study included patients with UC, CD, and indeterminate colitis, with UC and CD diagnosed by ICD codes. Information of participants, genotype platforms are available at the FinnGen website [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.finngen.fi/en/" ext-link-type="uri">https://www.finngen.fi/en/</ext-link>]. The dataset used comprised of 5,673 IBD patients and 213,119 control patients, including 4,320 patients with UC and 210,300 controls, as well as 2,056 patients with CD and 210,300 controls To minimize bias resulting from racial differences, the SNPs identified as instrumental variables (IVs) associated with lipid traits were obtained from the UK Biobank (<xref rid="B17" ref-type="bibr">17</xref>), and only SNPs from studies based on European ancestry were selected.</p></sec><sec id="s2_2"><label>2.2</label><title>Instrumental variable selection</title><p>In the univariable MR analyses, we applied rigorous quality control procedures to identify independent, eligible, and genome-wide significant SNPs (linkage disequilibrium, LD clumping r2 threshold = 0.001, window size = 10&#8201;Mb and <italic toggle="yes">p</italic>&#8201;&lt; 5&#215;10<sup>-8</sup>) associated with each trait, including HDL-C, LDL-C and TG. For MVMR analyses, SNPs were clumped with respect to the lowest <italic toggle="yes">P</italic>-value corresponding to each exposure in a multivariable model using a 1-Mb window and pairwise LD R<sup>2</sup>&#8201;&lt;&#8201;0.001. F-statistic was used to access the strength of instruments in univariable MR, and conditional F-statistic to access the strength in MVMR. The value of a statistic less than 10 were excluded to reduce weak instrument bias. We obtained the lipid-lowering drug targets related IVs from the Global Lipid Genetics Consortium (GLGC) for Drug-target MR analyses.</p><p>The IVs for lipid-lowering drug targets were from a GWAS of LDL-C conducted by the Global Lipid Genetics Consortium (GLGC) (linkage disequilibrium, LD r2 &#8804; 0.2, physical distance = 250 kb, window size =100 kb and <italic toggle="yes">p</italic>&#8201;&lt; 5&#215;10<sup>-8</sup>) (<xref rid="B18" ref-type="bibr">18</xref>). The targets included 3-Hydroxy-3-Methylglutaryl-CoA Reductase (<italic toggle="yes">HMGCR</italic>), NPC1 Like Intracellular Cholesterol Transporter 1(<italic toggle="yes">NPC1L1</italic>), Proprotein convertase subtilisin/kexin type 9 (<italic toggle="yes">PCSK9</italic>), Apolipoprotein B (<italic toggle="yes">APOB</italic>), Cholesteryl ester transfer protein (<italic toggle="yes">CETP</italic>), with each gene including 5,4,11,15,7 SNP that were used as IVs. Each lipid-lowering drug target corresponds to statins, ezetimibe, evolocumab &amp; alirocumab, anacetrapib and mipomersen, separately. For each SNP, the effect allele is significantly associated with lower concentrations of LDL-C. We ensured that there were no strong correlations between IVs of each trait (R2&#8201;&lt;&#8201;0.4 or R2&#8201;&lt;&#8201;0.3).</p></sec><sec id="s2_3"><label>2.3</label><title>MR analyses</title><p>
<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> illustrates the different methods we employed to conduct univariable and multivariable Mendelian randomization (MR) analyses, including simple median, weighted median, MR-Egger, MR robust adjusted profile score (MR.RAPS) (<xref rid="B19" ref-type="bibr">19</xref>) and inverse-variance weighted (IVW) method. Fixed-effect model IVW, which offers high efficiency and statistical power, was the primary method used (<xref rid="B20" ref-type="bibr">20</xref>). To assess heterogeneity and pleiotropy, we used Cochran&#8217;s Q statistic and the MR-Egger test (intercept). In cases where significant heterogeneity was present, we utilized the multiplicative random effects IVW method. Additionally, we employed the MR-radial method, robust regression, and outlying variants penalized to investigate the impact of outliers on the outcome (<xref rid="B21" ref-type="bibr">21</xref>, (<xref rid="B22" ref-type="bibr">22</xref>). In instances where horizontal pleiotropy was detected, we employed the MR-Egger test as the primary analysis method, while using MR-PRESSO to further correct for pleiotropy (<xref rid="B23" ref-type="bibr">23</xref>). For multivariable MR (MVMR) analyses, we utilized the multivariable IVW, multivariable MR-Egger, multivariable median-based, and multivariable MR-Lasso methods. We used the multivariable MR-Egger method for pleiotropy testing and Cochran&#8217;s Q statistic for heterogeneity testing. All MR analyses adhered to the STROBE-MR Statement (<xref rid="B24" ref-type="bibr">24</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Overview of the study design. GWAS, genome-wide association study; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn&#8217;s disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; IVW, inverse-variance weighted; RAPS, MR robust adjusted profile score; HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase; NPC1L1, NPC1 Like Intracellular Cholesterol Transporter 1; PCSK9, Proprotein convertase subtilisin/kexin type 9; APOB, Apolipoprotein B; CETP, Cholesteryl ester transfer protein; GLGC, Global Lipid Genetics Consortium; MR, Mendelian randomization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1160312-g001.jpg"/></fig><p>To investigate the causality of lipid-lowering drug targets in IBD,UC and CD, as well as the potential mediators involved, we performed network MR by conducting at least three two-sample MR tests among lipid-lowering drug targets, IBD/UC/CD, and potential mediators (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>We used publicly available genome-wide association study (GWAS) data. Relevant informed consent and ethical approval had already been obtained, so additional ethical approval was not required for this study. We conducted all statistical analyses using the &#8220;TwoSample MR&#8221; (version 0.5.6) and &#8220;MendelianRandomization&#8221; (version 0.5.1) packages in R software (version 4.1.1), with a statistical significance threshold of P value&#8201;&lt;&#8201;0.05.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>We identified 525, 218, and 435 SNPs as instrumental variables (IVs) for HDL-C, LDL-C, and TG, respectively (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;1</bold>
</xref>). The median F statistic of these IVs was 47.49 (with a quartile range of 35.56-84.49), indicating that our data were not susceptible to weak instrument bias.</p><sec id="s3_1"><label>3.1</label><title>Causal effect of lipids on IBD, UC and CD</title><p>Significant heterogeneity was observed between the independent variables (IVs) and the outcomes of IBD, UC, and CD, as indicated by Cochran&#8217;s Q test (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;2</bold>
</xref>, <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplemental Figures&#160;1&#8211;3</bold>
</xref>).</p><p>Therefore, the multiplicative random effects model, known as the inverse variance weighted (IVW) method, was used as the main model. Univariate MR analyses revealed a significant association between HDL-C and CD, with an OR of 0.85 (95% CI: 0.73-0.98, <italic toggle="yes">P</italic> = 0.024) for a one-standard deviation increase in HDL-C, as shown in <xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Univariable Mendelian randomization results using different methods. <bold>(A)</bold> IBD; <bold>(B)</bold> UC; <bold>(C)</bold> CD. IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn&#8217;s disease; SNP N, number of single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; IVW, inverse-variance weighted; RAPS, MR robust adjusted profile score.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1160312-g002.jpg"/></fig><p>To ensure the robustness of our results, we applied MR-radial method and robust regression and outlying variants (MR-RAPS) penalized analyses, which also showed a significant inverse association between HDL-C and CD, with ORs of 0.84 (95% CI: 0.73-0.97, <italic toggle="yes">P</italic> = 0.019) and 0.83 (95% CI: 0.72-0.96, <italic toggle="yes">P</italic> = 0.012), respectively, for a one-standard deviation increase in HDL-C. These findings are presented in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Tables&#160;3, 4</bold>
</xref> and <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplemental Figures&#160;4&#8211;7</bold>
</xref>.</p><p>Although some horizontal pleiotropy was detected in the MR analyses of HDL-C and IBD, and TG and CD, as shown by the MR-Egger test, the results of this test and the IVW analysis were consistent, indicating minimal impact of pleiotropy on the results. Furthermore, further analysis using the MR-PRESSO package yielded similar results, confirming the robustness of our findings (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;5</bold>
</xref>).</p></sec><sec id="s3_2"><label>3.2</label><title>Direct causal effect of lipids on IBD, UC and CD using multivariable MR</title><p>The present study used a multivariable Mendelian randomization (MVMR) approach, which incorporated three variables (HDL-C, LDL-C, and TG) to evaluate potential weak instrumental variable bias. The conditional F-statistic values corresponding to these variables were 68.7, 35.46, and 62.2, respectively, indicating no significant bias. Our MVMR analyses further revealed that higher HDL-C levels were inversely associated with the risk of IBD (OR: 0.87, 95% CI: 0.78-0.98, <italic toggle="yes">P</italic> = 0.026), UC (OR: 0.87, 95% CI: 0.77-0.99, <italic toggle="yes">P</italic> = 0.04), and CD (OR: 0.82, 95% CI: 0.69-0.97, <italic toggle="yes">P</italic> = 0.02), as shown in <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref> and <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;6</bold>
</xref>. Notably, pleiotropy test did not detect significant pleiotropy, as summarized in <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;7</bold>
</xref>.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>
<bold>(A)</bold> Multivariable Mendelian randomization results using the inverse-variance weighted method. <bold>(B)</bold> Network-MR diagram of CETP and CD. IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn&#8217;s disease; SNP N, number of single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; CETP, Cholesteryl ester transfer protein, &#8594;, causal association; &#8211; &#8211; &#8211; &#8211;, no causal association.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1160312-g003.jpg"/></fig></sec><sec id="s3_3"><label>3.3</label><title>Gene-specific analyses for drug proxy variants on IBD, UC and CD</title><p>
<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;8</bold>
</xref> displays the IVs related to lipid-lowering drug targets. In <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4</bold>
</xref>, drug-targeted MR analyses revealed that a one-SD decrease in LDL-C predicted by variants at or near <italic toggle="yes">PCSK9</italic> was associated with higher ORs of being diagnosed with IBD, UC, and CD with values of 1.75 (95%CI: 1.13-2.69, <italic toggle="yes">P</italic> = 0.011), 2.1 (95%CI: 1.28-3.42, <italic toggle="yes">P</italic> = 0.003), and 2.24 (95%CI: 1.11-4.5, <italic toggle="yes">P</italic> = 0.024), respectively. Conversely, a one-SD decrease in LDL-C predicted by variants at or near <italic toggle="yes">CETP</italic> was associated with a lower OR of CD with a value of 0.12 (95%CI: 0.03-0.51, <italic toggle="yes">P</italic> = 0.004), while no such association was observed for IBD or UC patients. <xref rid="f3" ref-type="fig">
<bold>Figure&#160;3B</bold>
</xref> and <xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;9</bold>
</xref> demonstrated that HDL-C mediated the causal pathway from variants at or near <italic toggle="yes">CETP</italic> to CD in network-MR. Additionally, the heterogeneity analysis and pleiotropy test revealed no significant heterogeneity or pleiotropy (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table&#160;10</bold>
</xref>). Furthermore, the leave-one-out analysis demonstrated that the drug-targeted MR results were robust, even after excluding a single single-nucleotide polymorphism (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplemental Figure&#160;8</bold>
</xref>).</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Drug target Mendelian randomization results. IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn&#8217;s disease; SNP N, number of single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HMGCR, 3-Hydroxy-3-Methylglutaryl-CoA Reductase; NPC1L1, NPC1 Like Intracellular Cholesterol Transporter 1; PCSK9, Proprotein convertase subtilisin/kexin type 9; APOB, Apolipoprotein B; CETP, Cholesteryl ester transfer protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1160312-g004.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>To the best of our knowledge, this study is the first to utilize MR analysis to investigate the relationship between lipids, lipid-lowering drugs, and IBD. Our findings suggest a causal association between elevated levels of HDL-C and a reduced risk of all three IBD diseases, including UC and CD. Additionally, the drug-targeted MR analysis indicates that inhibiting <italic toggle="yes">PCSK9</italic> leads to an increased risk of all three diseases, while suppressing <italic toggle="yes">CETP</italic> reduces the risk of CD.</p><p>Our findings are consistent with previous studies that observed significant reductions in HDL-C levels in IBD patients (<xref rid="B3" ref-type="bibr">3</xref>), UC patients (<xref rid="B26" ref-type="bibr">26</xref>) and CD patients (<xref rid="B27" ref-type="bibr">27</xref>), indicating that HDL-C may play a role in the development of IBD. However, large prospective studies that evaluate the causal relationship between HDL-C and IBD are lacking. HDL-C is widely recognized as a complex and pleiotropic anti-inflammatory particle that plays a critical role in protecting the cardiovascular system by promoting cholesterol efflux in vascular endothelial cells, stimulating prostacyclin synthesis, and inhibiting platelet-activating factor synthesis (<xref rid="B28" ref-type="bibr">28</xref>). Whether HDL-C plays a protective role in the pathogenesis of IBD by inhibiting inflammation requires further investigation.</p><p>
<italic toggle="yes">CETP</italic> primarily binds to HDL in the circulatory system, transporting cholesterol esters from HDL to LDL and VLDL (<xref rid="B29" ref-type="bibr">29</xref>). Our study found that inhibition of <italic toggle="yes">CETP</italic> could reduce the risk of CD. However, since variants in or near <italic toggle="yes">CETP</italic> are related to both HDL-C and LDL-C levels, it is challenging to differentiate whether the protective effect is due to changes in HDL-C or LDL-C. To address this issue, we conducted a network-MR analysis that indicated HDL-C, rather than LDL-C, mediated the causal relationship between <italic toggle="yes">CETP</italic> and CD. We did not find evidence of a mediating effect of <italic toggle="yes">CETP</italic> inhibitors on HDL-C in IBD and UC. This may be related to the complex metabolic pathways of HDL-C, which involve multiple components, including ATP-binding cassette transporter G1, ATP-binding cassette transporter A1, and lecithin cholesterol acyltransferase, in addition to <italic toggle="yes">CETP</italic> (<xref rid="B30" ref-type="bibr">30</xref>). Our study at least confirms that <italic toggle="yes">CETP</italic> does not regulate HDL-C in IBD and UC, suggesting the involvement of other molecules in its regulation that require further investigation.</p><p>In a previous MR study, no causal relationship was found between <italic toggle="yes">CETP</italic> and <italic toggle="yes">PCSK9</italic> inhibitors and IBD, UC, and CD (<xref rid="B31" ref-type="bibr">31</xref>). The discrepancy in results may be due to the different IVs used in our study, with our study using SNPs associated with LDL-C levels. Our study found a causal relationship between <italic toggle="yes">PCSK9</italic> inhibitors and IBD, UC, and CD. Interestingly, our study did not find a causal relationship between LDL-C and the three diseases, indicating that PCSK9 affects IBD, UC, and CD through means other than by reducing LDL-C. Although <italic toggle="yes">PCSK9</italic> was initially linked to elevated LDL-C, recent studies have found its involvement in atherosclerosis, viral infections, immune activation, and tumor progression (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). While <italic toggle="yes">PCSK9</italic> is less expressed in the gastrointestinal tract, serum <italic toggle="yes">PCSK9</italic> levels were significantly higher in UC patients and associated with disease activity (<xref rid="B34" ref-type="bibr">34</xref>). The <italic toggle="yes">PCSK9</italic> inhibitor could inhibit the activity of TLR4/NF-&#954;B to ameliorate colitis induced by 2,4,6-trinitrobenzene sulfonic acid (<xref rid="B35" ref-type="bibr">35</xref>). These findings appear to contradict our study, but further research is needed to fully understand the role of PCSK9 in the gastrointestinal tract. Studies using PCSK9 knockout mice have provided insight into interpreting our results. For instance, <italic toggle="yes">PCSK9<sup>-/-</sup>
</italic>mice had more severe fibrosing steatohepatitis and were more prone to hepatocellular carcinoma (<xref rid="B36" ref-type="bibr">36</xref>). More severe oxidative stress was found in <italic toggle="yes">PCSK99<sup>-/-</sup>
</italic>mice (<xref rid="B37" ref-type="bibr">37</xref>). In these studies, the variants of <italic toggle="yes">PCSK9</italic> variants involve a lifelong process that starts with embryonic development, which is different from the short-term effect of clinical drug use. Therefore, future research is necessary to explore the role of <italic toggle="yes">PCSK9</italic> in the gastrointestinal tract fully. Finally, our study did not establish a direct causal relationship between the <italic toggle="yes">HMGCR</italic> inhibitor and the three outcomes, suggesting that there is no direct causality between statins and IBD, UC, and CD.</p><p>Our study offers several notable strengths. Firstly, we utilized the largest lipid-related GWAS database to date, providing a robust theoretical basis for future treatment of IBD, UC, and CD by demonstrating the causal effect of HDL-C. Secondly, we employed drug target MR and network MR analysis to demonstrate the mediation effect of HDL-C in <italic toggle="yes">CETP</italic> on CD, and the causal effect of the <italic toggle="yes">PCSK9</italic> inhibitor on IBD, UC, and CD. These findings highlight the need for further research into the potential gastrointestinal side effects of long-term use of <italic toggle="yes">PCSK9</italic> inhibitors. Finally, we conducted detailed heterogeneity and pleiotropy tests, ensuring the reliability of our results. However, our study also has some limitations. The FinnGen study included only individuals of European ancestry, limiting the generalizability of our conclusions to other populations. Additionally, our drug target MR analysis reflects the impact of lifelong application of lipid-lowering drugs on outcomes, which may not accurately reflect the relationship between short-term use of these drugs and related outcomes.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>In conclusion, this study provided strong evidence for the causal impact of HDL-C on IBD, UC, and CD. Furthermore, we have identified HDL-C as a mediator in the causal pathway linking CETP inhibitors to CD. Genetically proxied inhibition of <italic toggle="yes">PCSK9</italic> increased the risk of IBD, UC and CD, while inhibition of <italic toggle="yes">CETP</italic> decreased the risk of CD. However, further research is needed to investigate the potential role of PCSK9 inhibitors in gastrointestinal disorders.</p></sec><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving human participants were reviewed and approved by The ethics committee of The First Affiliated Hospital of Guangzhou Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>HT, ZY and YD planned and designed the study, analyzed and interpreted the data, and wrote the manuscript. LL and XC analyzed the data and made the tables presented in the manuscript. LP and YD, as corresponding authors, made important advice in the study design, supervised and coordinated the study conduct process, revised the manuscript and tables, as well as reviewed and verified all the data, methods, and results. All authors contributed to the article and approved the submitted version.</p></sec></body><back><ack><title>Acknowledgments</title><p>We want to acknowledge the participants and investigators of the original studies that provided the GWAS data.</p></ack><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160312/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160312/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet_1.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet_2.xlsx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>SC</given-names></name><name name-style="western"><surname>Shi</surname><given-names>HY</given-names></name><name name-style="western"><surname>Hamidi</surname><given-names>N</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>FE</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Benchimol</surname><given-names>EI</given-names></name><etal/></person-group>. <article-title>Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies</article-title>. <source>Lancet</source> (<year>2017</year>) <volume>390</volume>:<page-range>2769&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/s0140-6736(17)32448-0</pub-id><pub-id pub-id-type="pmid">29050646</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sappati Biyyani</surname><given-names>RS</given-names></name><name name-style="western"><surname>Putka</surname><given-names>BS</given-names></name><name name-style="western"><surname>Mullen</surname><given-names>KD</given-names></name></person-group>. <article-title>Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease</article-title>. <source>J Clin Lipidol</source> (<year>2010</year>) <volume>4</volume>:<page-range>478&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jacl.2010.08.021</pub-id><pub-id pub-id-type="pmid">21122694</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koutroumpakis</surname><given-names>E</given-names></name><name name-style="western"><surname>Ramos-Rivers</surname><given-names>C</given-names></name><name name-style="western"><surname>Regueiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Hashash</surname><given-names>JG</given-names></name><name name-style="western"><surname>Barrie</surname><given-names>A</given-names></name><name name-style="western"><surname>Swoger</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Association between long-term lipid profiles and disease severity in a Large cohort of patients with inflammatory bowel disease</article-title>. <source>Dig Dis Sci</source> (<year>2016</year>) <volume>61</volume>:<page-range>865&#8211;71</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s10620-015-3932-1</pub-id><pub-id pub-id-type="pmid">26514677</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Dyslipidaemia is associated with severe disease activity and poor prognosis in ulcerative colitis: a retrospective cohort study in China</article-title>. <source>Nutrients</source> (<year>2022</year>) <volume>14</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/nu14153040</pub-id><pub-id pub-id-type="pmcid">PMC9330762</pub-id><pub-id pub-id-type="pmid">35893893</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voutilainen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hutri-K&#228;h&#246;nen</surname><given-names>N</given-names></name><name name-style="western"><surname>Tossavainen</surname><given-names>P</given-names></name><name name-style="western"><surname>Sipponen</surname><given-names>T</given-names></name><name name-style="western"><surname>Pitk&#228;nen</surname><given-names>N</given-names></name><name name-style="western"><surname>Laitinen</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel disease</article-title>. <source>Dig Liver Dis</source> (<year>2018</year>) <volume>50</volume>:<page-range>348&#8211;52</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.dld.2018.01.121</pub-id><pub-id pub-id-type="pmid">29426615</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ungaro</surname><given-names>R</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HL</given-names></name><name name-style="western"><surname>C&#244;t&#233;-Daigneault</surname><given-names>J</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></name><name name-style="western"><surname>Atreja</surname><given-names>A</given-names></name><name name-style="western"><surname>Colombel</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>Statins associated with decreased risk of new onset inflammatory bowel disease</article-title>. <source>Am J Gastroenterol</source> (<year>2016</year>) <volume>111</volume>:<page-range>1416&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ajg.2016.233</pub-id><pub-id pub-id-type="pmid">27296939</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lochhead</surname><given-names>P</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>H</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Ol&#233;n</surname><given-names>O</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>JF</given-names></name></person-group>. <article-title>Association between statin use and inflammatory bowel diseases: results from a Swedish, nationwide, population-based case-control study</article-title>. <source>J Crohns Colitis</source> (<year>2021</year>) <volume>15</volume>:<page-range>757&#8211;65</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa235</pub-id><pub-id pub-id-type="pmcid">PMC8247597</pub-id><pub-id pub-id-type="pmid">33216873</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crockett</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>RA</given-names></name><name name-style="western"><surname>St&#252;rmer</surname><given-names>T</given-names></name><name name-style="western"><surname>Schectman</surname><given-names>R</given-names></name><name name-style="western"><surname>Darter</surname><given-names>J</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study</article-title>. <source>Inflammation Bowel Dis</source> (<year>2012</year>) <volume>18</volume>:<page-range>1048&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/ibd.21822</pub-id><pub-id pub-id-type="pmcid">PMC3213287</pub-id><pub-id pub-id-type="pmid">21826766</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>L</given-names></name><name name-style="western"><surname>Scott</surname><given-names>MKD</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Kalesinskas</surname><given-names>L</given-names></name><name name-style="western"><surname>Habtezion</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>NH</given-names></name><etal/></person-group>. <article-title>Computational drug repositioning of atorvastatin for ulcerative colitis</article-title>. <source>J Am Med Inform Assoc</source> (<year>2021</year>) <volume>28</volume>:<page-range>2325&#8211;35</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/jamia/ocab165</pub-id><pub-id pub-id-type="pmcid">PMC8510297</pub-id><pub-id pub-id-type="pmid">34529084</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhamija</surname><given-names>P</given-names></name><name name-style="western"><surname>Hota</surname><given-names>D</given-names></name><name name-style="western"><surname>Kochhar</surname><given-names>R</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>A</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>A</given-names></name></person-group>. <article-title>Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis</article-title>. <source>Indian J Gastroenterol</source> (<year>2014</year>) <volume>33</volume>:<page-range>151&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12664-013-0420-4</pub-id><pub-id pub-id-type="pmid">24222372</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>D</given-names></name><name name-style="western"><surname>Boktor</surname><given-names>M</given-names></name><name name-style="western"><surname>Mortensen</surname><given-names>EM</given-names></name><name name-style="western"><surname>Frei</surname><given-names>CR</given-names></name><name name-style="western"><surname>Mansi</surname><given-names>I</given-names></name></person-group>. <article-title>Comparison of frequency of inflammatory bowel disease and noninfectious gastroenteritis among statin users versus nonusers</article-title>. <source>Am J Cardiol</source> (<year>2015</year>) <volume>115</volume>:<page-range>1396&#8211;401</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.amjcard.2015.02.035</pub-id><pub-id pub-id-type="pmid">25784517</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emdin</surname><given-names>CA</given-names></name><name name-style="western"><surname>Khera</surname><given-names>AV</given-names></name><name name-style="western"><surname>Kathiresan</surname><given-names>S</given-names></name></person-group>. <article-title>Mendelian randomization</article-title>. <source>Jama</source> (<year>2017</year>) <volume>318</volume>:<page-range>1925&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2017.17219</pub-id><pub-id pub-id-type="pmid">29164242</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#244;t&#233;-Daigneault</surname><given-names>J</given-names></name><name name-style="western"><surname>Mehandru</surname><given-names>S</given-names></name><name name-style="western"><surname>Ungaro</surname><given-names>R</given-names></name><name name-style="western"><surname>Atreja</surname><given-names>A</given-names></name><name name-style="western"><surname>Colombel</surname><given-names>JF</given-names></name></person-group>. <article-title>Potential immunomodulatory effects of statins in inflammatory bowel disease</article-title>. <source>Inflammation Bowel Dis</source> (<year>2016</year>) <volume>22</volume>:<page-range>724&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/mib.0000000000000640</pub-id><pub-id pub-id-type="pmid">26809008</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanderson</surname><given-names>E</given-names></name></person-group>. <article-title>Multivariable mendelian randomization and mediation</article-title>. <source>Cold Spring Harb Perspect Med</source> (<year>2021</year>) <volume>11</volume>. doi:&#160;<pub-id pub-id-type="doi">10.1101/cshperspect.a038984</pub-id><pub-id pub-id-type="pmcid">PMC7849347</pub-id><pub-id pub-id-type="pmid">32341063</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>AF</given-names></name><name name-style="western"><surname>Finan</surname><given-names>C</given-names></name><name name-style="western"><surname>Gordillo-Mara&#241;&#243;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Asselbergs</surname><given-names>FW</given-names></name><name name-style="western"><surname>Freitag</surname><given-names>DF</given-names></name><name name-style="western"><surname>Patel</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Genetic drug target validation using mendelian randomisation</article-title>. <source>Nat Commun</source> (<year>2020</year>) <volume>11</volume>:<fpage>3255</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-020-16969-0</pub-id><pub-id pub-id-type="pmid">32591531</pub-id><pub-id pub-id-type="pmcid">PMC7320010</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurki</surname><given-names>MI</given-names></name><name name-style="western"><surname>Karjalainen</surname><given-names>J</given-names></name><name name-style="western"><surname>Palta</surname><given-names>P</given-names></name><name name-style="western"><surname>Sipil&#228;</surname><given-names>TP</given-names></name><name name-style="western"><surname>Kristiansson</surname><given-names>K</given-names></name><name name-style="western"><surname>Donner</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>FinnGen: unique genetic insights from combining isolated population and national health register data</article-title>. <source>medRxiv</source> (<year>2022</year>).</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>TG</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>E</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>TM</given-names></name><name name-style="western"><surname>Ala-Korpela</surname><given-names>M</given-names></name><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable mendelian randomisation analysis</article-title>. <source>PloS Med</source> (<year>2020</year>) <volume>17</volume>:<elocation-id>e1003062</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pmed.1003062</pub-id><pub-id pub-id-type="pmid">32203549</pub-id><pub-id pub-id-type="pmcid">PMC7089422</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willer</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>EM</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Peloso</surname><given-names>GM</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>S</given-names></name><name name-style="western"><surname>Kanoni</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Discovery and refinement of loci associated with lipid levels</article-title>. <source>Nat Genet</source> (<year>2013</year>) <volume>45</volume>:<page-range>1274&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/ng.2797</pub-id><pub-id pub-id-type="pmcid">PMC3838666</pub-id><pub-id pub-id-type="pmid">24097068</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Small</surname><given-names>DS</given-names></name></person-group>. <article-title>Powerful three-sample genome-wide design and robust statistical inference in summary-data mendelian randomization</article-title>. <source>Int J Epidemiol</source> (<year>2019</year>) <volume>48</volume>:<page-range>1478&#8211;92</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ije/dyz142</pub-id><pub-id pub-id-type="pmid">31298269</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name><name name-style="western"><surname>Dudbridge</surname><given-names>F</given-names></name><name name-style="western"><surname>Gill</surname><given-names>D</given-names></name><name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Guidelines for performing mendelian randomization investigations</article-title>. <source>Wellcome Open Res</source> (<year>2019</year>) <volume>4</volume>:<fpage>186</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.12688/wellcomeopenres.15555.2</pub-id><pub-id pub-id-type="pmid">32760811</pub-id><pub-id pub-id-type="pmcid">PMC7384151</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Fall</surname><given-names>T</given-names></name><name name-style="western"><surname>Dudbridge</surname><given-names>F</given-names></name><name name-style="western"><surname>Gill</surname><given-names>D</given-names></name><name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants</article-title>. <source>Epidemiology</source> (<year>2017</year>) <volume>28</volume>:<fpage>30</fpage>&#8211;<lpage>42</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1097/ede.0000000000000559</pub-id><pub-id pub-id-type="pmid">27749700</pub-id><pub-id pub-id-type="pmcid">PMC5133381</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Spiller</surname><given-names>W</given-names></name><name name-style="western"><surname>Del Greco</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>N</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J</given-names></name><name name-style="western"><surname>Minelli</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Improving the visualization, interpretation and analysis of two-sample summary data mendelian randomization <italic toggle="yes">via</italic> the radial plot and radial regression</article-title>. <source>Int J Epidemiol</source> (<year>2018</year>) <volume>47</volume>:<page-range>1264&#8211;78</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ije/dyy101</pub-id><pub-id pub-id-type="pmcid">PMC6124632</pub-id><pub-id pub-id-type="pmid">29961852</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verbanck</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Neale</surname><given-names>B</given-names></name><name name-style="western"><surname>Do</surname><given-names>R</given-names></name></person-group>. <article-title>Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases</article-title>. <source>Nat Genet</source> (<year>2018</year>) <volume>50</volume>:<page-range>693&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41588-018-0099-7</pub-id><pub-id pub-id-type="pmcid">PMC6083837</pub-id><pub-id pub-id-type="pmid">29686387</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skrivankova</surname><given-names>VW</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>RC</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>BAR</given-names></name><name name-style="western"><surname>Yarmolinsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NM</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement</article-title>. <source>Jama</source> (<year>2021</year>) <volume>326</volume>:<page-range>1614&#8211;21</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1001/jama.2021.18236</pub-id><pub-id pub-id-type="pmid">34698778</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>RG</given-names></name></person-group>. <article-title>Network mendelian randomization study design to assess factors mediating the causal link between telomere length and heart disease</article-title>. <source>Circ Res</source> (<year>2017</year>) <volume>121</volume>:<page-range>200&#8211;2</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1161/circresaha.117.311387</pub-id><pub-id pub-id-type="pmid">28729448</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaghari Tabari</surname><given-names>M</given-names></name><name name-style="western"><surname>Moein</surname><given-names>S</given-names></name><name name-style="western"><surname>Qujeq</surname><given-names>D</given-names></name><name name-style="western"><surname>Kashifard</surname><given-names>M</given-names></name><name name-style="western"><surname>Shokri Shirvani</surname><given-names>J</given-names></name><name name-style="western"><surname>Hajian Tilaki</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Evaluation of the potential antioxidant role of high-density lipoprotein-cholesterol (HDL-c) in patients with ulcerative colitis</article-title>. <source>Iranian J Colorectal Res</source> (<year>2017</year>) <volume>5</volume>. doi: <pub-id pub-id-type="doi">10.5812/acr.13699</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soh</surname><given-names>H</given-names></name><name name-style="western"><surname>Chun</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Park</surname><given-names>S</given-names></name><name name-style="western"><surname>Kang</surname><given-names>EA</given-names></name><name name-style="western"><surname>Im</surname><given-names>JP</given-names></name><etal/></person-group>. <article-title>P797 crohn&#8217;s disease and ulcerative colitis was associated with different lipid profile disorders: a nationwide population-based study</article-title>. <source>J Crohn&#8217;s Colitis</source> (<year>2019</year>) <volume>13</volume>:<page-range>S521&#8211;1</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1093/ecco-jcc/jjy222.921</pub-id><pub-id pub-id-type="pmid">31691306</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barter</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>S</given-names></name><name name-style="western"><surname>Rye</surname><given-names>KA</given-names></name><name name-style="western"><surname>Anantharamaiah</surname><given-names>GM</given-names></name><name name-style="western"><surname>Navab</surname><given-names>M</given-names></name><name name-style="western"><surname>Fogelman</surname><given-names>AM</given-names></name></person-group>. <article-title>Antiinflammatory properties of HDL</article-title>. <source>Circ Res</source> (<year>2004</year>) <volume>95</volume>:<page-range>764&#8211;72</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1161/01.res.0000146094.59640.13</pub-id><pub-id pub-id-type="pmid">15486323</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charles</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kane</surname><given-names>JP</given-names></name></person-group>. <article-title>New molecular insights into CETP structure and function: a review</article-title>. <source>J Lipid Res</source> (<year>2012</year>) <volume>53</volume>:<page-range>1451&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1194/jlr.R027011</pub-id><pub-id pub-id-type="pmcid">PMC3540851</pub-id><pub-id pub-id-type="pmid">22679067</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poznyak</surname><given-names>AV</given-names></name><name name-style="western"><surname>Sukhorukov</surname><given-names>VN</given-names></name><name name-style="western"><surname>Eremin</surname><given-names>II</given-names></name><name name-style="western"><surname>Nadelyaeva</surname><given-names>II</given-names></name><name name-style="western"><surname>Gutyrchik</surname><given-names>NA</given-names></name><name name-style="western"><surname>Orekhov</surname><given-names>AN</given-names></name></person-group>. <article-title>HDL-based therapy: vascular protection at all stages</article-title>. <source>Biomedicines</source> (<year>2023</year>) <volume>11</volume>. doi:&#160;<pub-id pub-id-type="doi">10.3390/biomedicines11030711</pub-id><pub-id pub-id-type="pmcid">PMC10045384</pub-id><pub-id pub-id-type="pmid">36979690</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>AF</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>NB</given-names></name><name name-style="western"><surname>Gordillo-Mara&#241;&#243;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Charoen</surname><given-names>P</given-names></name><name name-style="western"><surname>Drenos</surname><given-names>F</given-names></name><name name-style="western"><surname>Kivimaki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease</article-title>. <source>Nat Commun</source> (<year>2021</year>) <volume>12</volume>:<fpage>5640</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41467-021-25703-3</pub-id><pub-id pub-id-type="pmid">34561430</pub-id><pub-id pub-id-type="pmcid">PMC8463530</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>D</given-names></name><name name-style="western"><surname>P&#246;ss</surname><given-names>J</given-names></name><name name-style="western"><surname>B&#246;hm</surname><given-names>M</given-names></name><name name-style="western"><surname>Marin</surname><given-names>R</given-names></name><name name-style="western"><surname>D'Inc&#224;</surname><given-names>R</given-names></name><name name-style="western"><surname>Gubbiotti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis</article-title>. <source>J Am Coll Cardiol</source> (<year>2013</year>) <volume>62</volume>:<page-range>1401&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jacc.2013.07.056</pub-id><pub-id pub-id-type="pmid">23973703</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seidah</surname><given-names>NG</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>D</given-names></name></person-group>. <article-title>Expanding biology of PCSK9: roles in atherosclerosis and beyond</article-title>. <source>Curr Atheroscler Rep</source> (<year>2022</year>) <volume>24</volume>:<page-range>821&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s11883-022-01057-z</pub-id><pub-id pub-id-type="pmcid">PMC9335453</pub-id><pub-id pub-id-type="pmid">35904732</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marinelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Zingone</surname><given-names>F</given-names></name><name name-style="western"><surname>Lupo</surname><given-names>MG</given-names></name><name name-style="western"><surname>Marin</surname><given-names>R</given-names></name><name name-style="western"><surname>D'Inc&#224;</surname><given-names>R</given-names></name><name name-style="western"><surname>Gubbiotti</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Serum levels of PCSK9 are increased in patients with active ulcerative colitis representing a potential biomarker of disease activity: a cross-sectional study</article-title>. <source>J Clin Gastroenterol</source> (<year>2022</year>) <volume>56</volume>:<page-range>787&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/mcg.0000000000001607</pub-id><pub-id pub-id-type="pmcid">PMC9988229</pub-id><pub-id pub-id-type="pmid">34560758</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZL</given-names></name><name name-style="western"><surname>He</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis <italic toggle="yes">via</italic> repressing toll-like receptor 4/nuclear factor-kappa b</article-title>. <source>Kaohsiung J Med Sci</source> (<year>2020</year>) <volume>36</volume>:<page-range>705&#8211;11</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/kjm2.12225</pub-id><pub-id pub-id-type="pmcid">PMC11896329</pub-id><pub-id pub-id-type="pmid">32396274</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ioannou</surname><given-names>GN</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SP</given-names></name><name name-style="western"><surname>Linsley</surname><given-names>PS</given-names></name><name name-style="western"><surname>Gersuk</surname><given-names>V</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>MM</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><etal/></person-group>. <article-title>Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: role of cholesterol</article-title>. <source>Hepatol Commun</source> (<year>2022</year>) <volume>6</volume>:<page-range>780&#8211;94</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1002/hep4.1858</pub-id><pub-id pub-id-type="pmcid">PMC8948564</pub-id><pub-id pub-id-type="pmid">34816633</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebeau</surname><given-names>PF</given-names></name><name name-style="western"><surname>Byun</surname><given-names>JH</given-names></name><name name-style="western"><surname>Platko</surname><given-names>K</given-names></name><name name-style="western"><surname>Al-Hashimi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lhot&#225;k</surname><given-names>&#352;</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>ME</given-names></name><etal/></person-group>. <article-title>Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice</article-title>. <source>JHEP Rep</source> (<year>2019</year>) <volume>1</volume>:<page-range>418&#8211;29</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jhepr.2019.10.009</pub-id><pub-id pub-id-type="pmcid">PMC7005770</pub-id><pub-id pub-id-type="pmid">32039393</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>